Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. - Wikidata - wikimedia - TriplyDB

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

http://www.wikidata.org/entity/Q37125079

about

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer Salpingectomy as a means to reduce ovarian cancer risk The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention"Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube Expression signatures of TP53 mutations in serous ovarian cancers.Glucocorticoid-induced reversal of interleukin-1β-stimulated inflammatory gene expression in human oviductal cells.Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?Tubal origin of ovarian low-grade serous carcinoma.IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis Estrogen biosynthesis and action in ovarian cancer.The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.IMP3 signatures of fallopian tube: a risk for pelvic serous cancers.Primary peritoneal carcinoma: regional cancer institute experience New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research Fallopian tube origin of supposed ovarian high-grade serous carcinomas.Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Fallopian tube prolapse after hysterectomy: a systematic review On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research.Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers.Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report.Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer.Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.Ovarian cancer survival by tumor dominance, a surrogate for site of origin.Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy.Primary peritoneal serous carcinoma: a clinicopathological and immunohistochemical study of six cases.Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

P2860

Q26822545-8AE80CF7-58A8-4C6E-97A7-8DA6C93D1B4F Q27008375-C0E40F62-0145-4E48-B05E-9BB61469B10D Q27009306-EDEF4596-C451-40F0-8D13-98D11ABFB6E0 Q27011949-EFC8F23D-DF8D-4453-821C-144A6D6BB266 Q27025315-035D4096-7D3F-4928-8875-4AEBBFEF884D Q27333756-ECB00B1F-09F6-48B1-8C4F-071266CC940C Q30250107-F8230BE5-F1BA-4F25-9653-391D5B4D01C3 Q33510967-1CE3BF05-C974-4FE7-84BA-4395A0E6F99D Q33588196-2B4C05BD-C9EA-4F8F-A74E-BCC32E5FDE4B Q33645478-4BF90304-16E2-4CDD-BAFD-15F56E9489E7 Q33761023-B7CCF8B5-C699-41DE-B672-E27ADC6429FB Q33815261-3BA586C5-8CFD-41A8-A898-FBE60F549EC8 Q33986711-BDE43CC0-C3FA-41D8-939A-9D4E8C9710C1 Q34039906-0AAE69B4-518F-4DC2-83E5-62EA1E8D3054 Q34111959-F03C828F-6793-4FAB-B9AA-02D7E9E936E6 Q34125241-44B3AA3E-CF11-427F-969B-A90ECA662372 Q34383567-9CC18A61-AE5C-48C2-9586-76BC9C918E6A Q34468574-2CCA6C61-43BF-4D29-914B-2BEF7D62E2C8 Q34496401-DCC302B4-4189-4C64-B21B-292A8A6D05FE Q34498581-565EBB24-F393-4B5D-965D-B67686F25ACF Q34504360-7F53A524-3C7D-4E5D-9320-A3D701776AC5 Q34534359-8250D9D5-E8D7-491D-9F87-5F67A886A882 Q34543315-C7955F43-DEBD-4F6A-A468-8EA55DEE5526 Q34604042-57E2DD9A-EEF5-44B5-AD25-F9487166C3BB Q34811314-C5743F71-0E9C-433C-846E-E21B6579C665 Q34990489-A32DD18D-BF46-4D86-AF5F-182737F44F54 Q34998994-EB4CC757-7CDE-4018-B9B0-E39F596256E8 Q35014713-A2920276-169D-49C9-89F0-C432A532DE46 Q35111420-F9F6BB58-B3C8-47E8-B4AE-C48DFDFE77F6 Q35134003-0FF0286C-69D5-4C33-99A4-C0053FD22410 Q35145201-A00217C2-F6D1-4922-B77A-5DF0CECE5B8C Q35195618-9564F6EF-9BF9-46E2-994B-F2AA6A0AC9FF Q35575368-38D620A4-A0B9-4C64-9978-B7AB9B440A78 Q35690548-6F7DC245-567A-4AF9-BE37-B212CF05A96A Q35808778-23BD75FC-8F14-45B8-980B-F8A810FA0F2A Q35925743-61B68F08-A872-4A39-8C41-0C17A4D0D1A6 Q36032691-C02FEE6E-924C-4BA0-B38A-F8E59DC286EE Q36219581-0F1E4F74-F182-490A-B03B-7C5AE2275D38 Q36305409-7702DAAA-8A11-4FDD-AC6A-05A45B4082C0 Q36309548-1CD07E2A-7761-49C1-81DA-649EAFCD2013

P2860

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

http://www.wikidata.org/entity/Q37125079

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Serous tubal intraepithelial c ...... and serous cancer prevention.

@en

Serous tubal intraepithelial c ...... and serous cancer prevention.

@nl

type

label

Serous tubal intraepithelial c ...... and serous cancer prevention.

@en

Serous tubal intraepithelial c ...... and serous cancer prevention.

@nl

prefLabel

Serous tubal intraepithelial c ...... and serous cancer prevention.

@en

Serous tubal intraepithelial c ...... and serous cancer prevention.

@nl

P1433

Q37125079-EC3463AD-E9F4-4816-BFA8-8A696CC629AE

P1476

Q37125079-33742CD4-E0E9-4473-91BD-E03E8EA22A1E

P2093

Q37125079-00440D80-E6BC-4309-8ADD-1B50A0C05655

Q37125079-6CA2E56F-0CC1-409B-9F84-B31F84A4DD7E

Q37125079-789F58B5-FD63-44B9-A93E-8F199A08A10C

Q37125079-BD6B364B-097B-4236-82B8-B01EC2D0970D

Q37125079-C3B2A49F-4B0C-4921-96CE-42CB2C46A462

Q37125079-C4875701-DA02-4E3F-90A7-AF8EE8670262

Q37125079-D2D54D8C-1BC2-44E3-A7CB-CE6C0D0CF73B

Q37125079-E13ABE69-DE28-438F-8529-A0609C6C159E

Q37125079-F83D982B-FD3F-4D4D-9DBA-FC78055274AF

P2860

Q37125079-08E416DC-57F4-46D7-9734-1CA32449172E

Q37125079-0B7D5B00-E1DE-4671-9A67-7D7C0135630D

Q37125079-199FAD02-1AB4-4D02-B734-66D51B15CCDB

Q37125079-228FD9D7-A017-4C49-8387-ADC2DC37EC2B

Q37125079-2D8EA66C-7664-487B-8425-3FE39F5B0601

Q37125079-32B6FD55-F2B7-448E-BB93-4E1656F74D23

Q37125079-35D2BAB3-4893-4C34-A005-CA764BDAA54B

Q37125079-3DB7F6DF-6936-462F-8C18-64C9CE942546

Q37125079-4C2365FA-243F-4D0A-AEB9-D647A538A94C

Q37125079-4D158D9B-32DB-4240-9273-942ABC840D7F

P304

Q37125079-78B55C34-2658-491B-AAD5-C602B8AF6193

P31

Q37125079-41E5A57F-3F41-4201-9B39-3855B179D8B1

P356

Q37125079-DFAD6A98-0CAD-4156-B278-7852599786EF

P407

Q37125079-3FA594B0-7AF2-4850-80C4-FA7B1AB5857A

P433

Q37125079-43677358-BD0F-4CDB-B6CA-51E4D744E98A

P478

Q37125079-000E2714-C968-4825-8A22-98C5AC4897F2

P577

Q37125079-B03F52F7-FD6A-4338-AB92-46F41BF6C484

P698

Q37125079-8A045FBE-6261-4207-928B-FAF736538E5A

P932

Q37125079-4F173B3C-AF74-4884-B94F-AE57B0F3D394

P356

JCO.2008.16.4814

P1433

Journal of Clinical Oncology

P1476

Serous tubal intraepithelial c ...... and serous cancer prevention.

@en

P2093

Alexander Miron

http://www.w3.org/2001/XMLSchema#string

Christopher P Crum

http://www.w3.org/2001/XMLSchema#string

David Kindelberger

http://www.w3.org/2001/XMLSchema#string

Elke A Jarboe

http://www.w3.org/2001/XMLSchema#string

Joseph W Carlson

http://www.w3.org/2001/XMLSchema#string

Mana M Parast

http://www.w3.org/2001/XMLSchema#string

Michael G Muto

http://www.w3.org/2001/XMLSchema#string

Michelle S Hirsch

http://www.w3.org/2001/XMLSchema#string

Yonghee Lee

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations.

Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.

P304

4160-4165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.16.4814

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18757330

http://www.w3.org/2001/XMLSchema#string

P932

2654373

http://www.w3.org/2001/XMLSchema#string